-- Enhance Pharmaceuticals Pack Task Descriptions
-- Pack IDs: 66666666-6666-6666-6666-000000000001 through 66666666-6666-6666-6666-000000000005
-- Total: 26 tasks across 5 packs

-- ============================================================================
-- PACK 1: Clinical Trial Planning (6 tasks)
-- Pack ID: 66666666-6666-6666-6666-000000000001
-- ============================================================================

UPDATE public.pack_items SET description = '**What to do:**
- Define primary endpoints that measure the main therapeutic effect
- Establish secondary endpoints for additional efficacy and safety measures
- Determine study population and sample size requirements
- Set statistical significance thresholds and power calculations
- Document hypothesis and expected outcomes

**Official resources:**
- [FDA IND Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-applications-prepared-and-submitted-sponsor-investigators) - sponsor-investigator IND submission requirements
- [ICH E9 Statistical Principles](https://www.ich.org/page/quality-guidelines) - statistical principles for clinical trials
- [ClinicalTrials.gov Protocol Registration](https://clinicaltrials.gov/ct2/manage-recs/protocol) - endpoint reporting requirements

**Key details:**
- Primary endpoint must be clinically meaningful and measurable
- FDA requires prospective endpoint definition before trial start
- Statistical analysis plan should be finalized before unblinding

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Define Trial Objectives%';

UPDATE public.pack_items SET description = '**What to do:**
- Draft comprehensive study protocol per ICH E6 R2 guidelines
- Define inclusion and exclusion criteria for participant selection
- Specify randomization and blinding procedures
- Detail dosing regimens, visit schedules, and assessments
- Establish safety monitoring and adverse event reporting procedures

**Official resources:**
- [ICH E6 R2 GCP Guidelines](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1) - integrated addendum for clinical practice
- [EU Clinical Trials Regulation](https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation) - EU 536/2014 requirements
- [FDA Protocol Template](https://www.fda.gov/science-research/science-and-research-special-topics/clinical-trials-and-human-subject-protection) - clinical trial protocol guidance

**Key details:**
- Protocol must be finalized before IRB submission
- Include detailed stopping rules and interim analysis plans
- All amendments require regulatory notification

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Design Trial Protocol%';

UPDATE public.pack_items SET description = '**What to do:**
- Identify potential clinical sites with appropriate patient populations
- Evaluate site capabilities, infrastructure, and regulatory compliance
- Assess investigator experience and qualification
- Conduct feasibility assessments and site visits
- Negotiate site agreements and establish enrollment targets

**Official resources:**
- [FDA Site Selection Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents) - clinical investigator responsibilities
- [EMA Clinical Trial Sites](https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines) - EU site requirements
- [ClinicalTrials.gov Facilities Database](https://clinicaltrials.gov/) - registered research facilities

**Key details:**
- Sites must have IRB approval before enrollment
- Geographic diversity may be required for regulatory acceptance
- Backup sites recommended to mitigate enrollment risk

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Select Trial Sites%';

UPDATE public.pack_items SET description = '**What to do:**
- Develop patient identification and screening strategies
- Create recruitment materials (ads, brochures, digital content)
- Establish referral networks with healthcare providers
- Set up pre-screening processes and eligibility verification
- Plan community outreach and patient education programs

**Official resources:**
- [FDA Recruitment Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/recruiting-study-subjects-guidance-institutional-review-boards-and-clinical-investigators) - IRB and investigator guidance on recruitment
- [NIH Recruitment Planning](https://grants.nih.gov/policy-and-compliance/policy-topics/clinical-trials) - NIH clinical trial recruitment requirements
- [ClinicalTrials.gov Registration](https://clinicaltrials.gov/ct2/manage-recs) - public trial listing for recruitment

**Key details:**
- All recruitment materials require IRB approval
- Informed consent process must comply with 21 CFR Part 50
- Track recruitment metrics and adjust strategies as needed

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Plan Patient Recruitment%';

UPDATE public.pack_items SET description = '**What to do:**
- Select and validate Electronic Data Capture (EDC) system
- Design case report forms (CRFs) aligned with protocol
- Establish database specifications and edit checks
- Implement 21 CFR Part 11 compliant audit trails
- Create data management plan and data cleaning procedures

**Official resources:**
- [FDA Electronic Records Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/electronic-systems-electronic-records-and-electronic-signatures-clinical-investigations-questions) - electronic systems Q&A (October 2024)
- [21 CFR Part 11](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11) - electronic records and signatures requirements
- [ICH E6 R2 Data Quality](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/e6r2-good-clinical-practice-integrated-addendum-ich-e6r1) - data integrity requirements

**Key details:**
- EDC system must be validated before first patient enrollment
- All data changes must be traceable with complete audit trail
- Database lock procedures must be documented

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Set Up Data Management%';

UPDATE public.pack_items SET description = '**What to do:**
- Prepare IRB/Ethics Committee submission package
- Include protocol, informed consent forms, and investigator brochure
- Submit to central and local IRBs as required
- Address IRB questions and requests for modifications
- Obtain written approval before initiating trial activities

**Official resources:**
- [FDA IRB Information](https://www.fda.gov/about-fda/cder-offices-and-divisions/institutional-review-boards-irbs-and-protection-human-subjects-clinical-trials) - IRB role and requirements
- [45 CFR 46 Common Rule](https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/index.html) - human subjects protection regulations
- [OHRP IRB Registration](https://ohrp.cit.nih.gov/efile/IRBRegistration.aspx) - IRB registration and oversight

**Key details:**
- IRB approval required before any study procedures
- Annual continuing review required for ongoing studies
- All protocol amendments require IRB approval

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000001'
AND title ILIKE '%Obtain Ethics Approval%';

-- ============================================================================
-- PACK 2: Regulatory Submission Preparation (5 tasks)
-- Pack ID: 66666666-6666-6666-6666-000000000002
-- ============================================================================

UPDATE public.pack_items SET description = '**What to do:**
- Identify optimal regulatory pathway (standard, accelerated, breakthrough)
- Develop submission timeline with key milestones
- Determine geographic filing strategy (US, EU, other regions)
- Plan pre-submission meetings with regulatory agencies
- Establish regulatory intelligence monitoring processes

**Official resources:**
- [FDA CDER Guidances](https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs) - comprehensive drug guidance documents
- [EMA Regulatory Pathways](https://www.ema.europa.eu/en/human-regulatory-overview) - EU regulatory procedures
- [FDA Pre-Submission Meetings](https://www.fda.gov/drugs/development-approval-process-drugs/meetings-between-fda-and-applicants) - meeting request guidance

**Key details:**
- Pre-IND meetings recommended for novel therapies
- Breakthrough therapy designation requires early application
- Consider parallel regulatory submissions for global efficiency

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000002'
AND title ILIKE '%Develop Regulatory Strategy%';

UPDATE public.pack_items SET description = '**What to do:**
- Compile Module 3 Chemistry, Manufacturing, and Controls documentation
- Document drug substance and drug product specifications
- Include manufacturing process descriptions and controls
- Provide stability data supporting shelf life claims
- Describe container closure systems and specifications

**Official resources:**
- [ICH M4 CTD Format](https://www.ich.org/page/ctd) - Common Technical Document organization
- [ICH Q8 Pharmaceutical Development](https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf) - development documentation requirements
- [FDA CMC Guidance](https://www.fda.gov/drugs/guidances-drugs/chemistry-manufacturing-and-controls-cmc-guidances) - CMC submission requirements

**Key details:**
- CMC data must support proposed commercial manufacturing
- Analytical methods must be validated per ICH guidelines
- Include batch analyses for clinical and stability batches

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000002'
AND title ILIKE '%Compile CMC Documentation%';

UPDATE public.pack_items SET description = '**What to do:**
- Compile Module 4 nonclinical study reports and summaries
- Include pharmacology, pharmacokinetics, and toxicology data
- Document carcinogenicity, reproductive toxicity studies as applicable
- Prepare integrated nonclinical summary and overview
- Address any safety signals from nonclinical studies

**Official resources:**
- [ICH M4S Nonclinical Overview](https://www.ich.org/page/ctd) - CTD nonclinical documentation format
- [ICH S Series Safety Guidelines](https://www.ich.org/page/safety-guidelines) - nonclinical safety studies
- [FDA Nonclinical Guidance](https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs) - preclinical study requirements

**Key details:**
- Nonclinical studies must support proposed clinical use
- GLP compliance required for pivotal safety studies
- Include SEND datasets for FDA submissions

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000002'
AND title ILIKE '%Prepare Nonclinical Summary%';

UPDATE public.pack_items SET description = '**What to do:**
- Compile Module 5 clinical study reports and data
- Prepare integrated clinical efficacy and safety summaries
- Document risk-benefit analysis for proposed indication
- Include individual patient data listings and analyses
- Address any safety concerns and mitigation strategies

**Official resources:**
- [ICH E3 Clinical Study Reports](https://database.ich.org/sites/default/files/E3_Guideline.pdf) - study report structure and content
- [ICH M4E Clinical Overview](https://www.ich.org/page/ctd) - CTD clinical documentation format
- [FDA Clinical Data Standards](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd) - eCTD clinical module requirements

**Key details:**
- All pivotal studies must be completed before submission
- Include CDISC-compliant datasets (SDTM, ADaM)
- Statistical analysis must follow pre-specified SAP

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000002'
AND title ILIKE '%Write Clinical Summary%';

UPDATE public.pack_items SET description = '**What to do:**
- Compile complete eCTD submission package
- Perform quality control review of all modules
- Submit NDA/BLA through FDA ESG or CTIS for EU
- Track submission receipt and validation status
- Prepare for information requests and deficiency letters

**Official resources:**
- [FDA eCTD Submission](https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/submit-using-ectd) - electronic submission requirements
- [FDA ESG Gateway](https://www.fda.gov/industry/electronic-submissions-gateway) - submission portal access
- [EU CTIS Portal](https://euclinicaltrials.eu/) - Clinical Trials Information System

**Key details:**
- eCTD v4.0 now supported for new NDAs and BLAs
- PDUFA user fees must accompany commercial submissions
- FDA has 60 days to determine filing acceptability

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000002'
AND title ILIKE '%Submit Application%';

-- ============================================================================
-- PACK 3: Manufacturing Process Development (5 tasks)
-- Pack ID: 66666666-6666-6666-6666-000000000003
-- ============================================================================

UPDATE public.pack_items SET description = '**What to do:**
- Design and optimize drug product formulation
- Conduct excipient compatibility studies
- Evaluate stability under various conditions (temperature, humidity, light)
- Assess bioavailability through in vitro and in vivo studies
- Document formulation development rationale and selection

**Official resources:**
- [ICH Q8 R2 Pharmaceutical Development](https://database.ich.org/sites/default/files/Q8%28R2%29%20Guideline.pdf) - Quality by Design principles
- [FDA Stability Testing Guidance](https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs) - stability study requirements
- [ICH Q1A Stability Testing](https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf) - stability data requirements

**Key details:**
- Stability studies must follow ICH Q1A conditions
- Bioequivalence may be required for formulation changes
- Document critical quality attributes (CQAs)

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000003'
AND title ILIKE '%Develop Formulation%';

UPDATE public.pack_items SET description = '**What to do:**
- Scale manufacturing process from laboratory to pilot to commercial
- Identify and control critical process parameters (CPPs)
- Conduct technology transfer to manufacturing facility
- Perform engineering and registration batches
- Document scale-up rationale and process changes

**Official resources:**
- [FDA Process Validation Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices) - three-stage validation approach
- [ICH Q10 Pharmaceutical Quality System](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - quality management during scale-up
- [ICH Q11 Drug Substance Development](https://database.ich.org/sites/default/files/Q11%20Guideline.pdf) - manufacturing process development

**Key details:**
- Scale-up should maintain equivalent product quality
- Process design space should be established
- Equipment qualification required at commercial scale

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000003'
AND title ILIKE '%Scale Up Process%';

UPDATE public.pack_items SET description = '**What to do:**
- Execute Stage 2 Process Performance Qualification (PPQ)
- Conduct minimum three consecutive successful validation batches
- Demonstrate process consistency and capability
- Document process parameters and acceptance criteria
- Prepare validation summary report

**Official resources:**
- [FDA Process Validation Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/process-validation-general-principles-and-practices) - Stage 1-2-3 validation lifecycle
- [ICH Q9 R1 Quality Risk Management](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q9r1-quality-risk-management) - risk-based validation approach
- [21 CFR 211 Subpart F](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-F) - production and process controls

**Key details:**
- All CPPs must be within validated ranges
- Pre-defined acceptance criteria required
- Continued process verification (Stage 3) required post-approval

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000003'
AND title ILIKE '%Validate Manufacturing Process%';

UPDATE public.pack_items SET description = '**What to do:**
- Develop and validate analytical test methods
- Perform method validation per ICH Q2 guidelines
- Establish specifications for identity, purity, potency, and impurities
- Document method transfer procedures
- Implement stability-indicating methods

**Official resources:**
- [ICH Q2 R2 Analytical Validation](https://database.ich.org/sites/default/files/Q2%28R2%29_Guideline_Step4_2024_0214.pdf) - validation parameters and criteria
- [USP General Chapters](https://www.usp.org/verification-services/reference-standards) - compendial methods and standards
- [FDA Analytical Procedures Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics) - method validation requirements

**Key details:**
- Methods must be validated before use in release testing
- Validation parameters: specificity, linearity, accuracy, precision, range
- System suitability tests required for routine use

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000003'
AND title ILIKE '%Establish Analytical Methods%';

UPDATE public.pack_items SET description = '**What to do:**
- Create master batch records and manufacturing instructions
- Document all process parameters, equipment, and materials
- Establish in-process controls and sampling procedures
- Define acceptance criteria and deviation handling
- Implement electronic batch record systems if applicable

**Official resources:**
- [21 CFR 211.186](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.186) - master production and control records
- [21 CFR 211.188](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.188) - batch production and control records
- [FDA Data Integrity Guidance](https://www.fda.gov/drugs/pharmaceutical-quality-resources/data-integrity-and-compliance-drug-cgmp) - electronic record requirements

**Key details:**
- All batch records must be reviewed before product release
- Deviations require investigation and CAPA
- Records must be retained for required period (1 year past expiry)

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000003'
AND title ILIKE '%Document Process%';

-- ============================================================================
-- PACK 4: Quality Management System (5 tasks)
-- Pack ID: 66666666-6666-6666-6666-000000000004
-- ============================================================================

UPDATE public.pack_items SET description = '**What to do:**
- Establish comprehensive Quality Management System framework
- Document quality policy and objectives
- Define organizational structure and responsibilities
- Create quality manual covering all GMP requirements
- Implement management review and continuous improvement processes

**Official resources:**
- [ICH Q10 Pharmaceutical Quality System](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - PQS model and elements
- [21 CFR Part 211](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211) - cGMP regulations for finished pharmaceuticals
- [FDA Quality Systems Approach](https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-systems-approach-pharmaceutical-cgmp-regulations) - modern quality systems guidance

**Key details:**
- Quality manual should address all ICH Q10 elements
- Senior management commitment required
- Include process performance and product quality monitoring

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000004'
AND title ILIKE '%Develop Quality Manual%';

UPDATE public.pack_items SET description = '**What to do:**
- Identify all GMP-critical processes requiring SOPs
- Write clear, step-by-step procedures for each process
- Include responsibilities, materials, equipment, and acceptance criteria
- Establish review, approval, and version control procedures
- Train personnel on new and revised SOPs

**Official resources:**
- [21 CFR 211.100](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-F/section-211.100) - written procedures for production and process control
- [FDA cGMP Facts](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp) - quality procedures requirements
- [ICH Q10](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - procedural controls guidance

**Key details:**
- SOPs must be available at point of use
- All deviations from SOPs require documentation
- Regular review cycle (typically annual) required

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000004'
AND title ILIKE '%Write Standard Operating Procedures%';

UPDATE public.pack_items SET description = '**What to do:**
- Implement document management system for GMP documents
- Establish document numbering, versioning, and archiving procedures
- Define review, approval, and change control workflows
- Ensure controlled document distribution and obsolete document retrieval
- Implement electronic document management system (EDMS) if applicable

**Official resources:**
- [21 CFR 211.180](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-J/section-211.180) - general records requirements
- [21 CFR Part 11](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11) - electronic records requirements
- [ICH Q10](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - knowledge management and documentation

**Key details:**
- All GMP documents must be approved before use
- Change control required for all document revisions
- Training records must be maintained

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000004'
AND title ILIKE '%Implement Document Control%';

UPDATE public.pack_items SET description = '**What to do:**
- Develop comprehensive GMP training curriculum
- Conduct initial and ongoing training for all personnel
- Include job-specific training and competency assessments
- Document all training with signatures and dates
- Implement training effectiveness evaluation

**Official resources:**
- [21 CFR 211.25](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-B/section-211.25) - personnel qualifications and training
- [FDA Training Requirements](https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practice-cgmp) - cGMP training expectations
- [ICH Q10](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - training and knowledge management

**Key details:**
- Training must be documented before performing GMP tasks
- Retraining required for significant procedure changes
- Annual GMP refresher training recommended

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000004'
AND title ILIKE '%Train Personnel%';

UPDATE public.pack_items SET description = '**What to do:**
- Schedule and conduct internal quality audits
- Perform mock regulatory inspections
- Identify and remediate compliance gaps
- Prepare inspection readiness documentation
- Train personnel on inspection behavior and communication

**Official resources:**
- [FDA Inspection Database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references) - inspection observations and trends
- [MHRA GMP Guide](https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice) - UK GMP inspection guidance
- [ICH Q10](https://database.ich.org/sites/default/files/Q10%20Guideline.pdf) - self-inspection and management review

**Key details:**
- Internal audits should cover all GMP areas annually
- CAPA must be implemented for audit findings
- Back room team should be prepared for inspections

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000004'
AND title ILIKE '%Prepare for Audits%';

-- ============================================================================
-- PACK 5: Drug Discovery Research (5 tasks)
-- Pack ID: 66666666-6666-6666-6666-000000000005
-- ============================================================================

UPDATE public.pack_items SET description = '**What to do:**
- Research disease biology and identify potential drug targets
- Validate target relevance through literature and experimental data
- Assess target druggability and tractability
- Evaluate competitive landscape for target
- Document target validation rationale and go/no-go criteria

**Official resources:**
- [NIH NCATS Preclinical Toolbox](https://ncats.nih.gov/research/research-resources/preclinical-research-toolbox) - target validation resources
- [Open Targets Platform](https://platform.opentargets.org/) - target-disease associations database
- [UniProt Database](https://www.uniprot.org/) - protein target information and annotations

**Key details:**
- Multiple validation approaches strengthen target confidence
- Consider genetic validation (GWAS, knockouts)
- Assess potential safety liabilities early

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000005'
AND title ILIKE '%Identify Drug Target%';

UPDATE public.pack_items SET description = '**What to do:**
- Design biochemical or cell-based screening assays
- Optimize assay conditions for HTS compatibility
- Validate assay performance (Z-factor, signal window)
- Establish positive and negative controls
- Document assay protocol and acceptance criteria

**Official resources:**
- [NIH Assay Guidance Manual](https://www.ncbi.nlm.nih.gov/books/NBK53196/) - comprehensive HTS assay guidance
- [NCATS Assay Development](https://ncats.nih.gov/research/research-resources/preclinical-research-toolbox) - assay development resources
- [PubChem BioAssay](https://pubchem.ncbi.nlm.nih.gov/bioassay) - assay protocols database

**Key details:**
- Z-factor > 0.5 indicates excellent assay quality
- Counter-screens needed to eliminate false positives
- Automation compatibility essential for HTS

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000005'
AND title ILIKE '%Develop Screening Assays%';

UPDATE public.pack_items SET description = '**What to do:**
- Select appropriate compound libraries for screening
- Execute high-throughput screening campaign
- Apply hit selection criteria and confirm primary hits
- Conduct counter-screens to eliminate false positives
- Prioritize hits for follow-up studies

**Official resources:**
- [ChEMBL Database](https://www.ebi.ac.uk/chembl/) - bioactive compounds with drug-like properties
- [PubChem Compound Database](https://pubchem.ncbi.nlm.nih.gov/) - chemical substances and bioactivities
- [NCATS Pharmaceutical Collection](https://ncats.nih.gov/research/research-resources/preclinical-research-toolbox/npc) - approved drug compounds for screening

**Key details:**
- Diverse libraries increase chance of novel hits
- Confirm hits with dose-response curves
- Consider PAINS (pan-assay interference compounds) filters

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000005'
AND title ILIKE '%Screen Compound Library%';

UPDATE public.pack_items SET description = '**What to do:**
- Design and synthesize compound analogs for SAR studies
- Optimize potency, selectivity, and physicochemical properties
- Improve ADMET properties (absorption, metabolism, toxicity)
- Conduct iterative design-make-test cycles
- Document structure-activity relationships

**Official resources:**
- [ADMETlab Prediction Platform](https://admet.scbdd.com/) - ADMET property predictions
- [SwissADME](http://www.swissadme.ch/) - pharmacokinetics and drug-likeness
- [ChEMBL SAR Data](https://www.ebi.ac.uk/chembl/) - structure-activity relationship data

**Key details:**
- Balance potency with drug-like properties
- Monitor for metabolic liabilities (CYP inhibition)
- Assess hERG liability for cardiac safety

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000005'
AND title ILIKE '%Optimize Lead Compounds%';

UPDATE public.pack_items SET description = '**What to do:**
- Evaluate lead compounds against development criteria
- Conduct preliminary safety and efficacy profiling
- Assess manufacturing feasibility and scalability
- Prepare candidate nomination package
- Present to governance committee for development decision

**Official resources:**
- [FDA IND Content Requirements](https://www.fda.gov/drugs/development-approval-process-drugs/step-3-clinical-research) - preclinical data requirements
- [ICH M3 R2 Nonclinical Safety](https://database.ich.org/sites/default/files/M3_R2__Guideline.pdf) - safety studies to support first-in-human
- [NIH Blueprint Neurotherapeutics](https://ncats.nih.gov/research/research-resources/preclinical-research-toolbox) - development candidate criteria

**Key details:**
- Development candidate should meet target product profile
- IND-enabling studies required before clinical trials
- Document risk assessment and mitigation strategies

---
Verified: February 2026'
WHERE pack_id = '66666666-6666-6666-6666-000000000005'
AND title ILIKE '%Select Development Candidate%';
